Guardian Asset Advisors LLC Boosts Position in Eli Lilly and Company (NYSE:LLY)

Guardian Asset Advisors LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 1.7% during the 3rd quarter, Holdings Channel reports. The fund owned 3,423 shares of the company’s stock after purchasing an additional 56 shares during the period. Eli Lilly and Company makes up about 2.1% of Guardian Asset Advisors LLC’s holdings, making the stock its 11th largest holding. Guardian Asset Advisors LLC’s holdings in Eli Lilly and Company were worth $3,035,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Morton Capital Management LLC CA grew its holdings in Eli Lilly and Company by 72.2% during the third quarter. Morton Capital Management LLC CA now owns 720 shares of the company’s stock worth $638,000 after acquiring an additional 302 shares during the period. BSN CAPITAL PARTNERS Ltd purchased a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $16,785,000. Clarus Wealth Advisors acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth approximately $659,000. Adirondack Trust Co. increased its holdings in shares of Eli Lilly and Company by 2.1% during the 3rd quarter. Adirondack Trust Co. now owns 4,682 shares of the company’s stock valued at $4,148,000 after purchasing an additional 95 shares in the last quarter. Finally, Wedmont Private Capital lifted its stake in shares of Eli Lilly and Company by 4.8% in the 3rd quarter. Wedmont Private Capital now owns 13,002 shares of the company’s stock valued at $11,681,000 after purchasing an additional 592 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock traded down $6.16 during trading hours on Thursday, reaching $913.58. The company had a trading volume of 312,448 shares, compared to its average volume of 3,006,222. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company has a market capitalization of $868.27 billion, a price-to-earnings ratio of 136.08, a PEG ratio of 2.78 and a beta of 0.42. The stock has a fifty day moving average of $906.72 and a 200-day moving average of $850.80.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. On average, equities analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on LLY. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Bank of America raised their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Finally, Citigroup assumed coverage on Eli Lilly and Company in a research note on Friday, September 13th. They set a “buy” rating and a $1,060.00 target price for the company. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $979.29.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.